Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tardif, J.-C.
Right arrow Articles by Talajic, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tardif, J.-C.
Right arrow Articles by Talajic, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Perindopril and prevention of atrial fibrillation

Jean-Claude Tardif* and Mario Talajic

Department of Medicine, Montreal Heart Institute and Université de Montréal, 5000 Belanger Street, Montreal, Canada H1T 1C8

* Corresponding author. Tel: +1 514 376 3330; fax: +1 514 593 2500. E-mail address: jean-claude.tardif{at}icm-mhi.org

Atrial fibrillation (AF) is a major health problem and has been described as one of two emerging cardiovascular epidemics at the turn of the century. It is the most frequent cardiac arrhythmia, affecting 5% of individuals aged over 65 years, and it is associated with an increased risk of stroke and a doubling of mortality. Hypertension has been shown to be the most prevalent, independent, and potentially modifiable risk factor for AF. The current treatment of patients with AF is inadequate. More than 50% of patients have recurrences of the arrhythmia within 12 months despite therapy with potent anti-arrhythmic drugs, thus new strategies to prevent AF are needed. There are several lines of evidence suggesting that renin–angiotensin system (RAS) inhibition may reduce the incidence of new-onset AF as well as AF recurrence. In experimental models, angiotensin-converting enzyme (ACE) inhibitors have been shown to decrease both atrial structural and functional remodelling and AF; these effects appear to be specific to RAS inhibition and to be independent of the haemodynamic benefits of blood pressure control. A recently published meta-analysis of 11 clinical studies suggested that RAS inhibition reduced the risk of AF occurrence by 28%. In a cohort study involving 12 000 patients with hypertension, ACE inhibition was associated with a reduced incidence of AF. The bulk of evidence to date suggests that ACE inhibition may be a novel target to prevent the recurrence of AF in patients with hypertension; however, this has not been tested in an adequately powered prospective trial. The ongoing Canadian Trial on Atrial Fibrillation–2 (CTAF-2) is therefore testing the hypothesis that perindopril, a long-acting ACE inhibitor with a high affinity for tissue ACE, will be effective in preventing recurrences of AF in patients with hypertension.

Key Words: Atrial fibrillation • Hypertension • ACE inhibition • Perindopril


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
M. Tendera
Introduction
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_E): E1 - E1.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.